1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Humira Biosimilar Adoption Starts Slow In Medicare

 
• By Michael McCaughan

US Medicare Payment Advisory Commission will be tracking adoption of Humira biosimilars – both because of the direct impact on costs in the Part D program, but also to test whether changes to the benefit design will work to encourage price competition.

Tortoise-at-start-line
Will biosimilar adalimumab win the formulary race eventually? • Source: Shutterstock

Only about 60% of enrollees in the US Medicare outpatient prescription drug program will be in plans that offer at least one biosimilar version of AbbVie Inc.’s Humira (adalimumab) in 2024, the Medicare Payment Advisory Commission staff reports.

Following the launch of nine biosimilar versions of adalimumab in the US in 2023, MedPAC is watching closely for an impact on the program

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.